GRCL News and Press, Gracell Biotechnologies Inc. From 09/06/23

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , ...

2023-08-14 11:40:24 ET Gracell Biotechnologies Inc. (GRCL) Q2 2023 Earnings Conference Call August 14, 2023, 08:00 AM ET Company Participants William Cao - Chairman, Chief Executive Officer Wendy Li - Chief Medical Officer Kevin Xie - Chief Financial Officer ...

Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portion Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in...

2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...

2023-08-07 14:12:24 ET Shares of Gracell Biotechnologies (NASDAQ: GRCL) were up by more than 16% as of 2 p.m. on Monday after the clinical-stage biotech company announced a private stock placement of $150 million dollars. The company is scheduled to report second-quarter earning...

2023-08-07 14:08:45 ET Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It’s no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation ...

2023-08-07 08:12:35 ET Global clinical-stage biopharmaceutical company, Gracell Biotechnologies ( NASDAQ: GRCL ) jumped 14% on pre-market hours on Monday as it entered into an agreement for the private placement of 138.9M shares (equivalent to 27.78M ADS), at a purchase price eq...

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors PR Newswire Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP...

SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of...

SAN DIEGO and SUZHOU and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of canc...